|
ChemicalBook Optimization Suppliers |
|
| 融点 | 120° | | 比旋光度 | D20 -72° (c = 0.5 in ethanol) | | 沸点 | 390.58°C (rough estimate) | | 比重(密度) | 1.0865 (rough estimate) | | 屈折率 | 1.4900 (estimate) | | 貯蔵温度 | Sealed in dry,2-8°C | | 溶解性 | DMF: 2 mg/ml; DMSO: 0.1 mg/ml; Ethanol: 20 mg/ml; Ethanol:PBS (pH 7.2)(1:2): 0.3 mg/ml | | 酸解離定数(Pka) | 14.59±0.40(Predicted) | | 色 | White to Yellow | | Merck | 14,319 | | InChI | InChI=1/C21H26O2/c1-3-10-21(23)12-9-19-18-6-4-14-13-15(22)5-7-16(14)17(18)8-11-20(19,21)2/h3,8,11,13,18-19,23H,1,4-7,9-10,12H2,2H3/t18-,19+,20+,21+/s3 | | InChIKey | VWAUPFMBXBWEQY-ANULTFPQSA-N | | SMILES | C[C@]12C=CC3=C4CCC(=O)C=C4CC[C@@]3([H])[C@]1([H])CC[C@@]2(O)CC=C |&1:1,14,16,20,r| |
| WGK Germany | 3 | | RTECS 番号 | KG7745000 | | HSコード | 2937.23.5050 |
| | アルトレノジスト Usage And Synthesis |
| 外観 | うすい黄色〜黄色, 結晶性粉末〜粉末 | | 溶解性 | エタノール及びアセトンに溶け、水にほとんど溶けない。 | | 効能 | 発情誘導薬 (獣医薬) | | 化学的特性 | Pale Yellow Solid | | 使用 | Altrenogest can be used as a synthetic progestational agent used in veterinary medicine for the control of estrus in mares and antineoplastic. | | 定義 | ChEBI: Altrenogest is a 3-hydroxy steroid. | | brand name | REGUMATE (Roussel-UCLAF, France). | | 副作用 | People exposed to altrenogest products have potential health risks. Reproductive adverse effects reported in women and girls include abnormal or absent menstrual cycles, and in men include decreased libido. Other adverse effects reported after exposure include headaches, fever, abdominal pain, nausea, diarrhea, vomiting, and rashes.
Altrenogest causes essentially no side effects in mares, and it may be used for prolonged periods. | | Veterinary Drugs and Treatments | Altrenogest (Regu-Mate) is indicated (labeled) to suppress estrus
in mares to allow a more predictable occurrence of estrus following
withdrawal of the drug. It is used clinically to assist mares to establish
normal cycles during the transitional period from anestrus
to the normal breeding season often in conjunction with an artificial
photoperiod. It is more effective in assisting in pregnancy attainment
later in the transition period. Some authors (Squires et
al. 1983) suggest selecting mares with considerable follicular activity
(mares with one or more follicles 20 mm or greater in size) for
treatment during the transitional phase. Mares that have been in
estrus for 10 days or more and have active ovaries are also considered
excellent candidates for progestin treatment.
Altrenogest is effective in normally cycling mares for minimizing
the necessity for estrus detection, for the synchronization of estrus,
and permitting scheduled breeding. Estrus will ensue 2 – 5 days after
treatment is completed and most mares ovulate between 8 – 15
days after withdrawal. Altrenogest is also effective in suppressing estrus expression in show mares or mares to be raced. Although the
drug is labeled as contraindicated during pregnancy, it has been
demonstrated to maintain pregnancy in oophorectomized mares
and may be of benefit in mares that abort due to sub-therapeutic
progestin
levels.
The product Matrix is labeled for synchronization of estrus
in sexually mature gilts that have had at least one estrous cycle.
Treatment with altrenogest results in estrus (standing heat) 4-9 days
after completion of the 14-day treatment period.
Altrenogest has been used in dogs for luteal insufficiency and as a
treatment to prevent premature delivery. |
|